The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study (pages 140–147)
Matthew A Roberts, Helen L Pilmore, Francesco L Ierino, Sunil V Badve, Alan Cass, Amit X Garg, Carmel M Hawley, Nicole M Isbel, Henry Krum, Elaine M Pascoe, Andrew M Tonkin, Liza A Vergara, Vlado Perkovic and for theBLOCADE Study Collaborative Group
Article first published online: 24 FEB 2015 | DOI: 10.1111/nep.12362
Summary at a Glance
This study aimed to reduce cardiovascular (CV) events among dialysis patients. This is a trial design paper for the feasibility of a randomized controlled trial to evaluate beta-blockade (carvedilol 3.125 mg bid titrated to 6.25 mg bid or heart rate threshold 55 beats per minute vs placebo) among patients on dialysis. The feasibility will inform recruitment, logistics and intra-dialytic hypotension. Findings will be used to design full-scale study on CV outcomes.